Systematic investigations of COVID-19 in 283 cancer patients
Jie Wang,Qibin Song,Yuan Chen,Zhijie Wang,Qian Chu,Hongyun Gong,Shangli Cai,Xiaorong Dong,Bin Xu,Weidong Hu,Qun Wang,Linjun Li,Jiyuan Yang,Zhibin Xie,Zhiguo Luo,Jing Liu,Xiuli Luo,Jie Ren,Zhiguo Rao,Xinhua Xu,Dongfeng Pan,Zuowei Hu,Gang Feng,Chiding Hu,Liqiong Luo,Hongda Lu,Ruizhi Ran,Jun Jin,Yanhua Xu,Yong Yang,Zhihong Zhang,Li Kuang,Runkun Wang,Youhong Dong,Jianhai Sun,Wenbing Hu,Tienan Yi,Hanlin Wu,Mingyu Liu,Jiachen Xu,Jianchun Duan,Zhengyi Zhao,Guoqiang Wang,Yu Xu,Jie He
DOI: https://doi.org/10.1101/2020.04.28.20083246
2020-01-01
Abstract:Background Cancer patients are considered to be highly susceptible to viral infections, however, the comprehensive features of COVID-19 in these patients remained largely unknown. The present study aimed to assess the clinical characteristics and outcomes of COVID-19 in a large cohort of cancer patients.
Design, Setting, and Participants Data of consecutive cancer patients admitted to 33 designated hospitals for COVID-19 in Hubei province, China from December 17, 2019 to March 18, 2020 were retrospectively collected. The follow-up cutoff date was April 02, 2020. The clinical course and survival status of the cancer patients with COVID-19 were measured, and the potential risk factors of severe events and death were assessed through univariable and multivariable analyses.
Results A total of 283 laboratory confirmed COVID-19 patients (50% male; median age, 63.0 years [IQR, 55.0 to 70.0]) with more than 20 cancer types were included. The overall mortality rate was 18% (50/283), and the median hospitalization stay for the survivors was 26 days. Amongst all, 76 (27%) were former cancer patients with curative resections for over five years without recurrence. The current cancer patients exhibited worse outcomes versus former cancer patients (overall survival, HR=2.45, 95%CI 1.10 to 5.44, log-rank p =0.02; mortality rate, 21% vs 9%). Of the 207 current cancer patients, 95 (46%) have received recent anti-tumor treatment, and the highest mortality rate was observed in the patients receiving recent chemotherapy (33%), followed by surgery (26%), other anti-tumor treatments (19%), and no anti-tumor treatment (15%). In addition, a higher mortality rate was observed in patients with lymphohematopoietic malignancies (LHM) (53%, 9/17), and all seven LHM patients with recent chemotherapy died. Multivariable analysis indicated that LHM ( p =0.001) was one of the independent factors associating with critical illness or death.
Conclusions This is the first systematic study comprehensively depicting COVID-19 in a large cancer cohort. Patients with tumors, especially LHM, may have poorer prognosis of COVID-19. Additional cares are warranted and non-emergency anti-tumor treatment should be cautiously used for these patients under the pandemic.
### Competing Interest Statement
The authors have declared no competing interest.
### Funding Statement
This work was supported by the CAMS Initiative for Innovative Medicine (CAMS 2020-I2M-CoV19-004). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
### Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The data that support the findings of this study are available from the corresponding author on reasonable request.